NCT05120570View on ClinicalTrials.gov

PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

September 19, 2024

Study Completion Date

March 31, 2028

Conditions
Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative NeoplasmLymphoma
Interventions
DRUG

VIC- 1911

25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER